Article

Correlation Between Bisophonates and Cancer

As reported by Reuters, patients taking bisphosphonates for osteoporosis for more than five years may be at greater risk for developing cancer of the oesophagus, according to a British study.

As reported by Reuters, patients taking bisphosphonates for osteoporosis for more than five years may be at greater risk for developing cancer of the oesophagus, according to a British study.

The article quotes Jane Green, of Oxford University's Cancer Epidemiology Unit, as saying, “We have to be concerned, but this is the first large study with long-term follow up that has found this effect, and it is just one observational study.”

“Also, because oesophageal cancer is uncommon, even a doubled risk is still a low risk," she said in a telephone interview.”

The research team included Green and colleagues from Britain’s Medicines and Healthcare products Regulatory Agency. The researchers examined data from the UK General Practice Research database to come up with their results.

Those with 10 or more prescriptions for bisphospponates, or with prescriptions over about five years, had nearly double the risk of oesophageal cancer. Those with one or more previous prescriotions for oral bispohosphonates had a 30% higher risk of developing oesophageal cancer as well.

While previoud research that used the same database “found no link between bisphosphonates and oesophageal cancer,” this study trackers the patients fro twice as long.

The article quotes Green as saying, “It's important to see our findings as part of a wider picture. These are very commonly prescribed drugs and we don't have enough information about the long-term risks and benefits.”

The report, “Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort,” appears in the British Medicine Journal.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.